Product
Artemether + Lumefantrine
Aliases
artemether:lumefantrine (2.5 mg:30 mg), bid over 3 days, from 1-4 tablets per dose
2 clinical trials
1 indication
Indication
MalariaClinical trial
Multicenter, Open-label, Single-arm Study to Evaluate the PK, Safety, Tolerability and Efficacy of a New Artemether:Lumefantrine (2.5 mg:30 mg) Dispersible Tablet in the Treatment of Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum MalariaStatus: Active (not recruiting), Estimated PCD: 2023-06-30
Clinical trial
Efficacy of Artesunate-amodiaquine (ASAQ) and Artemether-lumefantrine (AL) for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in LiberiaStatus: Completed, Estimated PCD: 2023-08-16